Cargando…

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET

(18)F-FP-(+)-DTBZ is a novel PET radiotracer targeting vesicular monoamine transporter type 2 (VMAT2). The goal was to explore the image features in normal human brains with (18)F-FP-(+)-DTBZ as a reference of molecular landmark for clinical diagnosis in Parkinson's disease (PD) and related dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Kun-Ju, Weng, Yi-Hsin, Hsieh, Chia-Ju, Lin, Wey-Yil, Wey, Shiaw-Pyng, Kung, Mei-Ping, Yen, Tzu-Chen, Lu, Chin-Song, Hsiao, Ing-Tsung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786914/ https://www.ncbi.nlm.nih.gov/pubmed/24098749 http://dx.doi.org/10.1371/journal.pone.0075952

Ejemplares similares

Quantitative study of (18)F-(+)DTBZ image: comparison of PET template-based and MRI based image analysis
por: Jung Lung, Hsu, et al.
Publicado: (2018)

Diagnostic value of striatal (18)F-FP-DTBZ PET in Parkinson’s disease
por: Liu, Xiu-Lin, et al.
Publicado: (2022)

Corrigendum: Diagnostic value of striatal (18)F-FP-DTBZ PET in Parkinson's disease
por: Liu, Xiu-Lin, et al.
Publicado: (2022)

Elucidating the Relationship Between Diabetes Mellitus and Parkinson’s Disease Using (18)F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2
por: Kong, Yanyan, et al.
Publicado: (2020)

Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo (18)F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging
por: Weng, Chi-Chang, et al.
Publicado: (2017)

Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [(18)F]AV-45 Positron Emission Tomography in Chinese Population
por: Huang, Kuo-Lun, et al.
Publicado: (2013)

Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes
por: Freeby, Matthew J., et al.
Publicado: (2015)

PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021)

A Purification Method of (18)F-FP-(+)-DTBZ via Solid-Phase Extraction With Combined Cartridges
por: Dai, Yuyin, et al.
Publicado: (2021)

Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease
por: Huang, Sheng-Yao, et al.
Publicado: (2018)

(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2021)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

Investigation of reactive astrogliosis effect on post-stroke cognitive impairment
por: Huang, Kuo-Lun, et al.
Publicado: (2020)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
por: Alwindi, Malik, et al.
Publicado: (2023)

Decreased defluorination using the novel beta-cell imaging agent [(18)F]FE-DTBZ-d4 in pigs examined by PET
por: Jahan, Mahabuba, et al.
Publicado: (2011)

Pharmacodynamic Analysis of Magnetic Resonance Imaging-Monitored Focused Ultrasound-Induced Blood-Brain Barrier Opening for Drug Delivery to Brain Tumors
por: Chu, Po-Chun, et al.
Publicado: (2013)

A Novel Individual Metabolic Brain Network for 18F-FDG PET Imaging
por: Huang, Sheng-Yao, et al.
Publicado: (2020)

Diagnostic accuracy of (18)F-FP-CIT PET for clinically uncertain Parkinsonian syndrome
por: Oh, Minyoung, et al.
Publicado: (2023)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang, Hung-Wei, et al.
Publicado: (2012)

Sleep disturbances in Taiwanese patients with Parkinson's disease
por: Lin, Yi‐Ying, et al.
Publicado: (2017)

Visual reading for [(18)F]Florzolotau ([(18)F]APN-1607) tau PET imaging in clinical assessment of Alzheimer’s disease
por: Lin, Huan-Chun, et al.
Publicado: (2023)

PET Imaging a MPTP-Induced Mouse Model of Parkinson’s Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [(18)F]-DTBZ (AV-133)
por: Toomey, James S., et al.
Publicado: (2012)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

Investigation of a Potential Scintigraphic Tracer for Imaging Apoptosis: Radioiodinated Annexin V-Kunitz Protease Inhibitor Fusion Protein
por: Liao, Mei-Hsiu, et al.
Publicado: (2011)

Simple, Rapid and Reliable Preparation of [(11)C]-(+)-α-DTBZ of High Quality for Routine Applications
por: Zhang, Jinming, et al.
Publicado: (2012)

Tau PET With (18)F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation
por: Huang, Chin-Chang, et al.
Publicado: (2019)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7v5s1uc80q2biqtdt1vm9picnr